A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

NCT02187861 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

163

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma

Interventions

DRUG: Venetoclax
DRUG: Bendamustine
DRUG: Rituximab

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]